Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Cormorant Asset Management, LP reported a buy of 251,600 additional shares of Rapport Therapeutics (NASDAQ:RAPP), as disclosed in its November 14, 2025, SEC filing. The newly reported position stands at 3,192,521 shares, valued at $94.82 million at quarter-end. The trade increased the stake by approximately $61.38 million, accounting for 0.31% of Cormorant’s $1.45 billion in reportable U.S. equity assets.Cormorant Asset Management, LP increased its holding in Rapport Therapeutics; post-trade, the position represents 6.54% of 13F AUM.Top holdings after the filing:  Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool